MDCO 2010

Drug Profile

MDCO 2010

Alternative Names: CU-2010; MDCO-2010

Latest Information Update: 27 Oct 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Curacyte AG
  • Developer The Medicines Company
  • Class Antifibrinolytics; Small molecules
  • Mechanism of Action Antifibrinolytic agents; Serine protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Surgical blood loss

Most Recent Events

  • 04 Oct 2012 Discontinued - Phase-II for Surgical blood loss in Germany (IV)
  • 04 Oct 2012 Discontinued - Phase-II for Surgical blood loss in Switzerland (IV)
  • 01 Mar 2012 The Medicines Company initiates enrolment in a phase IIb trial in Surgical blood loss in Switzerland (NCT01530399)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top